AbSci

AbSci

The global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues4.8m4.8m5.7m5.7m6.2m20.1m51.4m
% growth132 %-20 %(1 %)9 %223 %156 %
EBITDA(12.6m)(99.8m)(91.4m)(74.1m)(68.8m)(67.6m)(38.1m)
% EBITDA margin(263 %)(2086 %)(1590 %)(1296 %)(1107 %)(337 %)(74 %)
Profit(14.4m)(101m)(105m)(111m)(96.1m)(83.2m)(69.6m)
% profit margin(300 %)(2111 %)(1825 %)(1934 %)(1545 %)(415 %)(136 %)
EV / revenue-108.0x6.5x68.3x68.5x20.0x8.4x
EV / EBITDA--5.2x-0.4x-5.3x-6.2x-5.9x-11.3x
R&D budget11.4m44.6m58.9m48.1m---
R&D % of revenue239 %932 %1025 %841 %---
  • Edit
DateInvestorsAmountRound
-

N/A

-

N/A

Series B

$12.0m

Series C

$10.4m

Series D

$10.4m

Series D
N/A

$5.0m

Debt

$65.0m

Series E

N/A

Late VC

$125m

Late VC
N/A

$200m

Valuation: $1.4b

292.9x EV/LTM Revenues

-111.2x EV/LTM EBITDA

IPO
*
N/A

$75.2m

Post IPO Equity
Total Funding€207m

Recent News about AbSci

Edit
More about AbSciinfo icon
Edit

AbSci is a pioneering company in the biotech industry, focused on revolutionizing protein expression and biomanufacturing. The company operates in the biopharmaceutical market, serving clients that include pharmaceutical companies, biotech firms, and research institutions. AbSci's core innovation lies in its advanced protein expression platform, which features a semi-oxidizing cytoplasm and a dual inducible promoter system. These technologies allow for precise control over protein production rates, leading to higher quality and efficiency in drug manufacturing.

One of AbSci's standout offerings is SoluPure, a chromatography-free purification method that simplifies the downstream processing of proteins. This method removes bottlenecks typically associated with traditional purification techniques, making the production process faster and more cost-effective. AbSci's high-throughput workflow can generate cell lines that produce folded, active protein products in as little as three months, significantly reducing the time and resources needed for drug development.

AbSci's business model is built around providing cutting-edge biomanufacturing solutions that introduce efficiencies and cost savings to the biotech industry. The company makes money by partnering with pharmaceutical and biotech companies, offering them proprietary technologies and services that enhance their drug discovery and manufacturing processes. By doing so, AbSci aims to replace traditional mammalian expression platforms, such as CHO cells, with its more efficient and scalable solutions.

The company is supported by a group of experienced investors and is driven by a team of passionate, imaginative, and accomplished scientists. These professionals are dedicated to challenging established industry practices and creating extraordinary tools for drug discovery and manufacturing.

In summary, AbSci is a disruptive force in the biotech industry, offering innovative solutions that streamline protein production and purification, ultimately transforming how life-changing biologics are made.

Keywords: Biotech, Protein Expression, Biomanufacturing, Drug Discovery, SoluPure, Purification, High-Throughput, Cytoplasm, Promoter System, Biopharmaceutical.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by AbSci

Edit
Totient
ACQUISITION by AbSci Jun 2021
Denovium
ACQUISITION by AbSci Jan 2021